This hypothesis is supported by reports showing that caffeine, which is metabolized primarily by CYP1A2 [134-136], can significantly protect against or reverse AD-like cognitive impairment and Aβ neuropathology in Alzheimer's disease mouse models [137]. Here, CYP1A2 is linked to Alzheimer disease.